ID   OC-3-VGH
AC   CVCL_GT37
DR   BCRC; 60599
DR   ChEMBL-Cells; CHEMBL4630772
DR   ChEMBL-Targets; CHEMBL4630780
DR   PubChem_Cell_line; CVCL_GT37
DR   Wikidata; Q54931708
RX   PubMed=1611619;
RX   PubMed=3455323;
CC   Population: Chinese.
CC   Doubling time: 48 hours (PubMed=3455323).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 29-06-23; Version: 8
//
RX   PubMed=1611619; DOI=10.1007/BF01741050; PMCID=PMC11038318;
RA   Lee C.-Y.G., Chen K.-W., Sheu F.-S., Tsang A., Chao K.-C., Ng H.-T.;
RT   "Studies of a tumor-associated antigen, COX-1, recognized by a
RT   monoclonal antibody.";
RL   Cancer Immunol. Immunother. 35:19-26(1992).
//
RX   PubMed=3455323;
RA   Chao K.-C., Ng H.-T., Chang C.-C.;
RT   "Characteristics of a newly established ovarian carcinoma cell
RT   line -- OC-3-VGH.";
RL   Zhonghua Yi Xue Za Zhi (Taipei) 39:147-152(1987).
//